Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Anemia is common in patients with chronic heart failure (CHF).

This study aimed to examine the frequency of iron deficiency anemia in patients with CHF.

The researchers investigated the effects of oral ferrous or ferric supplementation on prognosis of CHF and quality of life.

Who Took Part

The abstract describes 201 patients taking part.

The age groups tagged for this paper are older adults, both men and women.

A total of 201 patients with chronic decompensated heart failure were enrolled in a 6-month prospective study.

Patients were randomly assigned to two groups.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

Patients in group I (n = 100) received ferrous fumarate and those in group II (n = 101) received ferric hydroxide polymaltose complex.

Quality of life was measured by the 6-minute walking test (6MWT).

What Was Measured

PubMed files the paper under topics including Anemia, Iron-Deficiency, Chronic Disease, Dietary Supplements, Ferric Compounds, Ferrous Compounds, Heart Failure and Hematinics.

The authors tagged it with the keywords hemoglobin, iron deficiency, iron supplement and quality of life.

What This Means in Plain Language

The paper is a randomized study of Copper (Supplement) in 201 patients.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (The Journal of international medical research), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.